국가: 아일랜드
언어: 영어
출처: HPRA (Health Products Regulatory Authority)
Norton Healthcare Limited T/A IVAX Pharmaceuticals UK
400 mg Milligram
Tablets
1983-08-02
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PA0282/026/002 Case No: 2061908 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to NORTON HEALTHCARE LIMITED T/A IVAX PHARMACEUTICALS UK REGENT HOUSE, 5-7 BROADHURST GARDENS, SWISS COTTAGE, LONDON NW6 3RZ, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product METRONIDAZOLE TABLETS BP 400MG. the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 30/06/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 30/06/2010_ _CRN 2061908_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Metronidazole Tablets BP 400mg. 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 400 mg of metronidazole. Excipient: Lactose monohydrate 150mg For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Tablet. White, circular, biconvex tablets having a diameter of 12.5 mm. Coded ‘MZL 400’ with breakline on one face, twin triangle logo on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS In the treatment of urogenital trichomoniasis. In the treatment of acute ulcerative gingivitis. In the treatment of infections due to _E. histolytica _(including 전체 문서 읽기